Bacterial ConjunctivitisPhase 3NCT01227863
Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
A Phase 3 study testing MAXINOM® and Maxitrol® in people with Bacterial Conjunctivitis and Acute, run by Azidus Brasil at 1 site in Brazil.
Trial summary
The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Bacterial Conjunctivitis, Acute
- What is being tested?
- MAXINOM® and Maxitrol®
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- 1 siteBrazil
- Study dates
- Feb 2011to Feb 2011
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who agree with all study procedures and sign, by his own free will, IC;
- Adult patients, regardless of gender, ethnicity or social status, with good mental health;
- Patients who present at screening visit, picture of acute bacterial conjunctivitis diagnosed clinically.
Who cannot join
- Patients with clinical diagnosis or suspicion of conjunctivitis due to any process that is not due to bacterial infection, such as infections by fungi, protozoa, viruses and allergic conjunctivitis;
- Patients with known hypersensitivity to any component of the formulas of the study drugs;
- Patients with a history or clinical diagnosis of other lesions that may affect the outcome, such as glaucoma, corneal ulcer or scars;
- Concomitant use of ocular medication other than the study;
- Pregnant or lactating women;
- Being or having been treated for any type of conjunctivitis within 15 days and have finished treatment or less than 07 days
Trial locations and contacts
1 site in 1 country.
Brazil1 site
LAL Clinica Pesquisa e Desenvolvimento Ltda
Valinhos, São Paulo
Alexandre Frederico, doctor, 55 19 3871-6399, alexandre@lalclinica.com.br
Jose Roberto de Camargo, doctor
About this study
Official title: Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.
Read the detailed description
- Evaluation of isolated signs and symptoms during treatment, with a record of individual scores for each parameter and observation
- Statistical comparison of drug safety, by recording qualitative and quantitative parameters related to adverse effects occurring during treatment.
- Conditions
- Bacterial Conjunctivitis, Acute
- Being tested
- MAXINOM®, Maxitrol®
- Keywords
- SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS
- Medical subject headings
- Conjunctivitis, Bacterial
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MAXINOM®Drug
Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
Maxitrol®Drug
Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
| Study group | Role | What they receive |
|---|---|---|
| Test | Experimental | Dexamethasone + neomycyn + polimixyn B Receives: Drug: MAXINOM® |
| Comparator | Active comparator | Dexamethasone + neomycyn + polimixy B Receives: Drug: Maxitrol® |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compared effectiveness between drugs using percentage of improvement (sustained response rate) at the end of treatment.
There will be a total of three returns after inclusion (0 day), and they are 1, 3 and 7 days after initiation of treatment. At the returns of 1 and 3 days there will be a tolerance of + 1 day and the return of 7 day, the tolerance will be +- 1 day. On each return will be collected data on the efficacy and safety.
Measured: 7 dyas of treatment.
Secondary outcomes (2)
Evaluation of signs and symptoms during treatment with a record of individual scores for each parameter established.
There will be a total of three returns after inclusion (0 day), and they are 1, 3 and 7 days after initiation of treatment. At the returns of 1 and 3 days there will be a tolerance of + 1 day and the return of 7 day, the tolerance will be +- 1 day. On each return will be collected data on the efficacy and safety.
Measured: 7 days of treatment.
Statical comparison of drug safety by recording qualitative and quantitative parameter related to adverse effects occurring during treatment.
There will be a total of three returns after inclusion (0 day), and they are 1, 3 and 7 days after initiation of treatment. At the returns of 1 and 3 days there will be a tolerance of + 1 day and the return of 7 day, the tolerance will be +- 1 day. On each return will be collected data on the efficacy and safety.
Measured: 7 days of treatment.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2010 (estimated)
- Study startFeb 2011
- Primary completionFeb 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bacterial ConjunctivitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Azidus Brasil
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01227863
- Sponsor's protocol ID
- DNPUNI0610
- Other IDs
- Version 01
- Status last verified
- Oct 2010
- First submitted
- 15 Oct 2010
- Last updated
- 25 Oct 2010
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Oct 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis
- ClinicalTrials.gov ID
- NCT01227863
- Acronym / sponsor ID
- DNPUNI0610
- Conditions
- Bacterial Conjunctivitis, Acute
- Keywords
- SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Azidus BrasilIndustry (pharma, biotech, devices)
- Study start
- Feb 2011
- Primary completion
- Feb 2011 (estimated)
- First posted
- 25 Oct 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.
Detailed description
- Evaluation of isolated signs and symptoms during treatment, with a record of individual scores for each parameter and observation
- Statistical comparison of drug safety, by recording qualitative and quantitative parameters related to adverse effects occurring during treatment.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Test | Experimental | Drug: MAXINOM®Dexamethasone + neomycyn + polimixyn B |
| Comparator | Active comparator | Drug: Maxitrol®Dexamethasone + neomycyn + polimixy B |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients who agree with all study procedures and sign, by his own free will, IC;
Key exclusion criteria (6 listed)
- Patients with clinical diagnosis or suspicion of conjunctivitis due to any process that is not due to bacterial infection, such as infections by fungi, protozoa, viruses and allergic conjunctivitis;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MAXINOM®Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1% | Drug | Test |
| Maxitrol®Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1% | Drug | Comparator |
Primary outcome
Compared effectiveness between drugs using percentage of improvement (sustained response rate) at the end of treatment.
Time frame: 7 dyas of treatment.
There will be a total of three returns after inclusion (0 day), and they are 1, 3 and 7 days after initiation of treatment. At the returns of 1 and 3 days there will be a tolerance of + 1 day and the return of 7 day, the tolerance will be +- 1 day. On each return will be collected data on the efficacy and safety.
2 secondary outcomes
Evaluation of signs and symptoms during treatment with a record of individual scores for each parameter established.
Time frame: 7 days of treatment.
Statical comparison of drug safety by recording qualitative and quantitative parameter related to adverse effects occurring during treatment.
Time frame: 7 days of treatment.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Oct 2010.
Related trials for Bacterial Conjunctivitis
Not yet recruitingPhase 4
Evaluation of the Impact of Oral Ivermectin on Musca Sorbens Flies, Putative Vector of Trachoma
Survival of Flies Developing in Faecal Samples
RecruitingPhase 1/2
Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
Bacterial Conjunctivitis
RecruitingObservational study
Development of a Mobile Terminal-Based Intelligent Detection System for Multiple Anterior Segment Diseases of the Eye
Artifical Intelligence, Cataract
RecruitingObservational study
Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface
Dry Eye Syndrome, Infectious Keratoconjunctivitis
Recruiting
RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)
Trachoma, Eye Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
LAL Clinica Pesquisa e Desenvolvimento Ltda
Valinhos, Brazil
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing MAXINOM® and Maxitrol® in people with Bacterial Conjunctivitis and Acute, run by Azidus Brasil at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compared effectiveness between drugs using percentage of improvement (sustained response rate) at the end of treatment. (time frame: 7 dyas of treatment.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2010.